Alnylam Pharmaceuticals, Inc.
ALNY
$251.56
$8.953.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -278.16M | -332.26M | -72.94M | -332.08M | -440.24M |
| Total Depreciation and Amortization | 56.67M | 58.21M | 54.71M | 53.46M | 54.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 427.26M | 417.19M | 482.28M | 445.63M | 433.08M |
| Change in Net Operating Assets | -214.08M | -86.58M | -91.78M | 22.10M | 57.26M |
| Cash from Operations | -8.31M | 56.56M | 372.26M | 189.12M | 104.16M |
| Capital Expenditure | -34.28M | -40.49M | -53.39M | -61.29M | -62.21M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -82.56M | -264.09M | -231.71M | -266.46M | -274.14M |
| Cash from Investing | -116.84M | -304.59M | -285.10M | -327.75M | -336.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 302.95M | 297.57M | 214.34M | 130.95M | 147.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8.79M | 4.82M | 18.44M | 23.72M | 24.67M |
| Cash from Financing | 294.16M | 302.39M | 232.77M | 154.67M | 172.13M |
| Foreign Exchange rate Adjustments | -15.24M | 12.93M | -8.72M | -5.73M | 6.39M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 153.77M | 67.29M | 311.22M | 10.31M | -53.67M |